ClinicalTrials.gg
RecruitingNCT06659445Updated Sep 10, 2026

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

A Phase 2 interventional study of ONL1204 Opthalmic solution and Avacincaptad Pegol intravitreal solution in Geographic Atrophy (GA) and Age - Related Macular Degeneration (AMD), sponsored by ONL Therapeutics. Recruiting at 120 sites in 12 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by ONL Therapeutics · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
18th of 107
324 · median 98
Started
2025
with 19 others
Phase 2
43 of 131
11 open now
Primary completion
2028-11
later than 31 of 44 live
Registered
103rd of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 18th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 43 in phase 2, reaches primary completion later than 31 of the 44 other live ones, and was the 103rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD.

GA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.

03

Conditions studied

  • Geographic Atrophy (GA)
  • Age - Related Macular Degeneration (AMD)

Keywords

  • Phase 2
  • ONL1204
  • Geographic Atrophy (GA)
  • Age-related Macular Degeneration (AMD)
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 55 years of age or older at Screening.
  2. Able and willing to give and attend study visits.
  3. Women or intersex individuals must be willing to use 2 forms of effective during the study and for at least 90 days following the last dose of study drug, be for at least 12 months prior to study entry, or surgically sterile. If of , a negative urine pregnancy test is required at Screening and prior to the administration of study drug at each visit.
  4. Men or intersex individuals with partners of childbearing potential must be willing to use permissible methods of contraception and refrain from sperm donation during the study and for at least 90 days following the last dose of study drug.
  5. If currently using Age-related Eye Disease Study 2 (AREDS, AREDS2, or similar nutraceutical therapy at Screening, patient must be willing to continue use for the duration of the study. If not currently using AREDS2 or similar, patient must be willing to continue not to use therapy for the duration of the study. Patient must agree to choose either approach.

    Study Eye Inclusion Criteria:

  6. BCVA of 24 letters or more using ETDRS charts in the study eye at Screening.
  7. Intraocular pressure (IOP) of 22 mmHg or lower in the study eye at Screening.

    The GA lesion must meet all the following criteria:

  8. Non-foveal GA associated with AMD without eMNV in the study eye per Investigator's evaluation and as confirmed by the central RC.
  9. GA ≥0.85 disc area (DA) (2.125 mm2) and ≤8.05 DA (20.125 mm2) in the study eye as confirmed by the central RC.
  10. If GA in the study eye is multifocal, at least 1 focal lesion must be ≥0.425 DA (1.063 mm2) as confirmed by the central RC.
  11. Non-foveal GA (GA lesion up to the fovea, but not subfoveal) with the lesion's closest border 1725 microns or less from the foveal center in the study eye, as confirmed by the central RC.
  12. The entire GA lesion in the study eye must be completely visualized on the macula-centered FAF image, must be able to be imaged in its entirety, and must not be contiguous with any areas of peripapillary atrophy per the Investigator's evaluation and as confirmed by the central RC.
  13. A pattern of hyper-autofluorescence in the junctional zone of GA in the study eye must be present as confirmed by the central RC.

    Fellow Eye Inclusion Criterion:

  14. BCVA of 19 letters or more using ETDRS charts in the fellow eye at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Current or planned participation in another clinical study or use of any other investigational drugs or devices at least 6 months prior to enrollment or during the study period without prior written Sponsor approval.
  2. Previous ophthalmic disease gene therapy or planned participation in any gene therapy clinical study during the study period.
  3. Current or planned use of systemic complement inhibitors during the study period.
  4. Any ocular or systemic condition that, in the opinion of the Investigator, makes the patient unsuitable for treatment with an investigational drug or that would compromise the safety or efficacy assessments of the study.
  5. Treatment with any ocular or systemic medication that is known to be toxic to the lens, retina, or optic nerve (including, but not limited to, aminoglycosides, vancomycin, hydroxychloroquine, interferon, tacrolimus, cisplatin, bis-chloroethyl nitrosourea, carmustine, ethambutol, and tamoxifen) within 90 days prior to Screening or anticipated during the study period.
  6. Any previous treatment of pentosan polysulfate (Elmiron®) is exclusionary.
  7. Known allergy to fluorescein, povidone iodine, or any ingredients of the study drug or avacincaptad pegol intravitreal solution.
  8. Individuals who are currently pregnant, planning to become pregnant, or are nursing at Screening or during the study period.

    Study Eye Exclusion Criteria:

  9. Active ocular or periocular infection in the study eye.
  10. Any to an IVT injection in the study eye.
  11. Any media opacity in the study eye that limits visual acuity, clinical visualization of the retina, or retinal imaging as determined by the Investigator.
  12. Previous IVT pharmaceutical treatment in the study eye with any agent except Food and Drug Administration (FDA)-approved complement inhibitors and treatment with FDA-approved complement inhibitors within 12 weeks prior to Screening.
  13. Any history of incisional retinal surgery in the study eye including but not limited to scleral buckle or vitrectomy. (Retinal laser for a tear or hole 3 months or more prior to Screening is not exclusionary).
  14. History of incisional glaucoma surgery including trabeculectomy, tube shunt, or minimally invasive glaucoma surgery in the study eye. (Glaucoma laser procedures performed at least 6 months prior to Screening are not exclusionary).
  15. Yttrium aluminum garnet capsulotomy in the study eye within 1 month prior to Screening.
  16. Cataract surgery in the study eye planned or expected during the study period.
  17. Aphakia with absence of the posterior capsule in the study eye. (Pseudophakia with an open posterior capsule is not exclusionary).
  18. Any current evidence or history in the study eye of exudative ("wet") AMD, including any RPE rips or evidence of actively leaking neovascularization anywhere in the retina based on the FA or SD-OCT as assessed per the Investigator's evaluation and confirmed by the central RC.
  19. Any retinal disease other than AMD except benign degenerative conditions (eg, Cobblestone degeneration) in the study eye.
  20. Intraocular surgery in the study eye (including lens replacement surgery) within 3 months prior to Screening. See Exclusion Criteria 12 and 13 pertaining to retinal and glaucoma surgery, respectively.
  21. Previous therapeutic radiation (including transpupillary thermotherapy, photodynamic therapy, or external-beam) in the region of the study eye.

    Fellow Eye Exclusion Criterion:

  22. Planned or expected IVT injection in the fellow eye for treatment of GA with agents other than FDA-approved complement inhibitors (pegcetacoplan or avacincaptad pegol IVT solution [Izervay™]) during the study period.

    Either Eye Exclusion Criteria:

  23. Active intraocular inflammation in either eye or a history of uveitis or endophthalmitis in either eye.
  24. GA in either eye due to causes other than AMD.
  25. Any ophthalmic condition in either eye that is likely to require surgery during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
324 participants (estimated)

Study arms

  • Active comparator
    ONL1204 Opthalmic solution (1 of 6 Treatment Groups) administered by intravitreal injection

    ONL1204 100 µg administered by intravitreal (IVT) injection every 12 weeks

    Drug: ONL1204 Opthalmic solution

  • Active comparator
    ONL1204 Opthalmic solution (2 of 6 Treatment Groups) administered by intravitreal injection

    ONL1204 200 µg administered by intravitreal (IVT) injection every 12 weeks

    Drug: ONL1204 Opthalmic solution

  • Experimental
    ONL1204 Opthalmic solution (3 of 6 Treatment Groups) administered by intravitreal injection

    ONL1204 200 µg administered by intravitreal (IVT) injection every 24 weeks

    Drug: ONL1204 Opthalmic solution

  • Sham comparator
    Sham Comparator (4 of 6 Treatment Groups)

    Sham injection every 12 weeks

    Other: Sham

  • Sham comparator
    Sham Comparator (5 of 6 Treatment Groups)

    Sham injection every 24 weeks

    Other: Sham

  • Active comparator
    Avacincaptad pegol intravitreal solution (6 of 6 Treatment Groups - US ONLY)

    Avacincaptad pegol administered by intravitreal (IVT) injection - (2 mg (0.1 mL of 20 mg/mL solution) once monthly

    Drug: Avacincaptad Pegol intravitreal solution

Interventions

  • DrugONL1204Studies of ONL1204ONL1204 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection

  • DrugAvacincaptad Pegol intravitreal solution

    Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection

  • OtherSham

    Sham injection

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    GA lesion area

    Time frame: From enrollment to the end of treatment at 48 weeks.

Secondary outcomes

  1. Secondary Endpoints (Safety)

    Incidence of new active exudative macular neovascularization (eMNV) in the study eye

    Time frame: From enrollment to the end of treatment at 48 weeks.

  2. Secondary Endpoints (Safety)

    Incidence of Early Treatment of Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) loss

    Time frame: From enrollment to the end of treatment at 48 weeks.

07

Study locations

120 of 120 sites recruiting
  • Associated Retina Consultants
    Gilbert, Arizona 85297, United States
    Recruiting
    • Study Coordinator · Contact
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
    Recruiting
    • Study Coordinator · Contact
  • California Retina Consultants
    Bakersfield, California 93309, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
    Recruiting
    • Study Coordinator · Contact
  • Macula and Retina Institute
    Glendale, California 91203, United States
    Recruiting
    • Study Coordinator · Contact
  • Salehi Retina Institute, dba Retina Associates of Southern California
    Huntington Beach, California 92647, United States
    Recruiting
    • Study Coordinator · Contact
  • Desert Retina Consultants
    Palm Desert, California 92211, United States
    Recruiting
    • Study Coordinator · Contact
  • Retinal Consultants Medical Group
    Sacramento, California 95841, United States
    Recruiting
    • Study Coordinator · Contact
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Southern Colorado
    Colorado Springs, Colorado 80909-1183, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
    Recruiting
    • Study Coordinator · Contact
  • Florida Retina Institute
    Orlando, Florida 32806, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Group of Florida
    Sarasota, Florida 34232, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609-4614, United States
    Recruiting
    • Study Coordinator · Contact
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
    Recruiting
    • Study Coordinator · Contact
  • The University of Chicago Medicine Duchossois Center for Advanced Medicine
    Chicago, Illinois 60637, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Associates, Ltd.
    Elmhurst, Illinois 60126, United States
    Recruiting
    • Study Coordinator · Contact
  • Illinois Retina Associates, S.C.
    Oak Park, Illinois 60304, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Partners Midwest, P.C.
    Carmel, Indiana 46032, United States
    Recruiting
    • Study Coordinator · Contact
  • The Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
    Recruiting
    • Study Coordinator · Contact
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Specialists
    Towson, Maryland 21204, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Research Institute at New England Retina Consultants
    Springfield, Massachusetts 01107, United States
    Recruiting
    • Study Coordinator · Contact
  • University of Michigan Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Study Coordinator · Contact
  • Associated Retinal Consultants, P.C.
    Royal Oak, Michigan 48073, United States
    Recruiting
    • Study Coordinator · Contact
  • Associated Retinal Consultants, P.C.
    Traverse City, Michigan 49686, United States
    Recruiting
    • Study Coordinator · Contact
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Study Coordinator · Contact
  • The Retina Institute
    St Louis, Missouri 63128, United States
    Recruiting
    • Study Coordinator · Contact
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Vitreous Surgeons of CNY, PC
    Liverpool, New York 13088, United States
    Recruiting
    • Study Coordinator · Contact
  • Ophthalmic Consultants of Long Island
    Oceanside, New York 11572, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Associates of Western NY
    Rochester, New York 14620, United States
    Recruiting
    • Study Coordinator · Contact
  • Long Island Vitreoretinal Consultants
    Westbury, New York 11590, United States
    Recruiting
    • Study Coordinator · Contact
  • North Carolina Retina Associates
    Cary, North Carolina 27511, United States
    Recruiting
    • Study Coordinator · Contact
  • Duke Eye Center
    Durham, North Carolina 27710, United States
    Recruiting
    • Study Coordinator · Contact
  • North Carolina Retina Associates
    Greenville, North Carolina 27834, United States
    Recruiting
    • Study Coordinator · Contact
  • North Carolina Retina Associates, S.C.
    Wake Forest, North Carolina 27587, United States
    Recruiting
    • Study Coordinator · Contact
  • Cleveland Clinic Foundation-Cole Eye Institute
    Cleveland, Ohio 44195, United States
    Recruiting
    • Study Coordinator · Contact
  • Erie Retina Research, LLC (Clinic)
    Erie, Pennsylvania 16505, United States
    Recruiting
    • Study Coordinator · Contact
  • Charleston Neuroscience Institute
    Mt. Pleasant, South Carolina 29464, United States
    Recruiting
    • Study Coordinator · Contact
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
    Recruiting
    • Study Coordinator · Contact
  • Vanderbilt Eye Institute
    Nashville, Tennessee 37232, United States
    Recruiting
    • Study Coordinator · Contact
  • Austin Retina Associates
    Austin, Texas 78705, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Texas
    Beaumont, Texas 77707, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Texas
    Katy, Texas 77494, United States
    Recruiting
    • Study Coordinator · Contact
  • Valley Retina Institute, P.A.
    McAllen, Texas 78503, United States
    Recruiting
    • Study Coordinator · Contact
  • Medical Center Ophthalmology Associates, LLP
    San Antonio, Texas 78240, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Associates of South Texas, PA
    San Antonio, Texas 78240, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Texas
    San Antonio, Texas 78240, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Center of Texas
    Southlake, Texas 76092, United States
    Recruiting
    • Study Coordinator · Contact
  • Retina Consultants of Texas
    The Woodlands, Texas 77384, United States
    Recruiting
    • Study Coordinator · Contact
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
    Recruiting
    • Study Coordinator · Contact
  • Pacific Northwest Retina
    Bellevue, Washington 98004, United States
    Recruiting
    • Study Coordinator · Contact
  • Pacific Northwest Retina, PLLC
    Silverdale, Washington 98383, United States
    Recruiting
    • Study Coordinator · Contact
  • Konventhospital der Barmherzigen Brüder Linz Abteilung für Augenheilkunde
    Linz, Austria 4020, Austria
    Recruiting
    • Study Coordinator · Contact
  • Medizinische Universität Wien
    Vienna, Austria 1090, Austria
    Recruiting
    • Study Coordinator · Contact
  • Vienna Institute for Research in Ocular Surgery - A Karl-Landsteiner-Institute
    Vienna, Austria 1140, Austria
    Recruiting
    • Study Coordinator · Contact
  • St. Joseph's Health Care London - Ivey Eye Institute
    London, Ontario N6A4V2, Canada
    Recruiting
    • Study Coordinator · Contact
  • Toronto Retina Institute
    Toronto, Ontario M3C0G9, Canada
    Recruiting
    • Study Coordinator · Contact
  • Toronto Western Hospital, University Health Network
    Toronto, Ontario M5T 2S8, Canada
    Recruiting
    • Study Coordinator · Contact
  • Clinique d'ophtalmologie des Laurentides
    Boisbriand, Quebec J7H0E8, Canada
    Recruiting
    • Study Coordinator · Contact
  • VISUS spol. s.r.o.
    Náchod, Czech Republic 574 01, Czechia
    Recruiting
    • Study Coordinator · Contact
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, Czech Republic 100 34, Czechia
    Recruiting
    • Study Coordinator · Contact
  • VFN Praha
    Prague, Czech Republic 128 08, Czechia
    Recruiting
    • Study Coordinator · Contact
  • Axon Clinical, s.r.o.
    Prague, Czech Republic 150 00, Czechia
    Recruiting
    • Study Coordinator · Contact
  • NEMOS Medical Private Care s.r.o.
    Sokolov, Czech Republic 356 01, Czechia
    Recruiting
    • Study Coordinator · Contact
  • Augen-Zentrum-Nordwest
    Ahaus, Germany 48683, Germany
    Recruiting
    • Study Coordinator · Contact
  • Universitäts-Augenklinik Bonn
    Bonn, Germany 53127, Germany
    Recruiting
    • Study Coordinator · Contact
  • Internationale Innovative Ophthalmochirurgie GbR c/o MVZ Breyer Kaymak Klabe Augenchirurgie
    Düsseldorf, Germany 40549, Germany
    Recruiting
    • Study Coordinator · Contact
  • Augenzentrum Prof. Dr. Koch GmbH
    Frankfurt am Main, Germany 60549, Germany
    Recruiting
    • Study Coordinator · Contact
  • Philipps-Universität Marburg
    Marburg, Germany 35043, Germany
    Recruiting
    • Study Coordinator · Contact
  • Uniklinikum Würzburg
    Würzburg, Germany 97080, Germany
    Recruiting
    • Study Coordinator · Contact
  • General Hospital of Athens "G. Gennimatas", 1st University Eye Clinic
    Athens, Greece 11527, Greece
    Recruiting
    • Study Coordinator · Contact
  • University General Hospital "Attikon", 2nd Department of Ophthalmology, University of Athens
    Athens, Greece 12462, Greece
    Recruiting
    • Study Coordinator · Contact
  • University General Hospital of Heraklion
    Heraklion, Greece 70013, Greece
    Recruiting
    • Study Coordinator · Contact
  • University General Hospital of Ioannina, Ophthalmology Clinica
    Ioannina, Greece 45500, Greece
    Recruiting
    • Study Coordinator · Contact
  • University General Hospital of Patras, Department of Ophthalmology
    Pátrai, Greece 26504, Greece
    Recruiting
    • Study Coordinator · Contact
  • Észak-Pesti Centrumkórház-Honvédkórház, Szemészeti Osztály
    Budapest, Hungry 1062, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Semmelweis Egyetem, Szemészeti Klinika Kutatóközpont
    Budapest, Hungry 1085, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Budapesti Bajcsy-Zsilinszky Kórház és Rendelőintézet, Szemészeti Osztály
    Budapest, Hungry 1106, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Budapest Retina Associates, Opthalmology
    Budapest, Hungry 1133, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Budapesti Jahn Ferenc Dél-pesti Kórház és Rendelőintézet, Szemészeti Osztály
    Budapest, Hungry 1204, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Debreceni Egyetem Klinikai Központ, Szemklinika
    Debrecen, Hungry 4032, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Pécsi Tudományegyetem Klinikai Kozpont, Szemeszeti Klinika
    Pécs, Hungry 7623, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szemészeti Klinika
    Szeged, Hungry 6720, Hungary
    Recruiting
    • Study Coordinator · Contact
  • Oculomedica Sp. z o.o.
    Bydgoszcz, Poland 85-157, Poland
    Recruiting
    • Study Coordinator · Contact
  • Optimum Profesorskie Centrum Okulistyki sp. z o.o.
    Gdansk, Poland 80-180, Poland
    Recruiting
    • Study Coordinator · Contact
  • Szpital Św. Róży sp. z o. o. sp. k.
    Krakow, Poland 30-394, Poland
    Recruiting
    • Study Coordinator · Contact
  • Centrum Medyczne Dietla 19 sp. z o.o.
    Krakow, Poland 31-070, Poland
    Recruiting
    • Study Coordinator · Contact
  • Klinika Okulistyczna Jasne Blonia sp. z o.o
    Lodz, Poland 91-134, Poland
    Recruiting
    • Study Coordinator · Contact
  • Bonifraterskie Centrum Medyczne sp. z o.o.
    Lodz, Poland 93-357, Poland
    Recruiting
    • Study Coordinator · Contact
  • Centrum Diagnostyki I Mikrochirurgii Oka Lens sp. Z o.o.
    Olsztyn, Poland 10-424, Poland
    Recruiting
    • Study Coordinator · Contact
  • AIBILI
    Coimbra, Portugal 3000-548, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Unidade Local de Saúde de Coimbra
    Coimbra, Portugal 3004-561, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Unidade Local de Saude de Gaia/Espinho
    Gaia, Portugal 4434-502, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Unidade Local De Saude De Santo Antonio
    Porto, Portugal 4050-011, Portugal
    Recruiting
    • Study Coordinator · Contact
  • Centro de Oftalmología Barraquer
    Barcelona, Spain 08021, Spain
    Recruiting
    • Study Coordinator · Contact
  • Institut Catalâ de Retina
    Barcelona, Spain 08022, Spain
    Recruiting
    • Study Coordinator · Contact

Showing the first 100 of 120 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2028, 37 months after the start.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 26, 2024
StartActual
Oct 28, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06659445
Lead sponsor
ONL Therapeutics
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Oct 28, 2025
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Study Coordinator
Contact
info@onltherapeutics.com
734-412-8787

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONL1204

Start the discussion